Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TD 1473

Drug Profile

TD 1473

Alternative Names: JNJ-8398; TD-1473

Latest Information Update: 27 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theravance Biopharma
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase II Crohn's disease

Most Recent Events

  • 21 May 2019 Efficacy data from a phase Ib trial in Ulcerative colitis released by Theravance Biopharma
  • 18 May 2019 Efficacy data from a phase Ib trial in Ulcerative colitis presented at the Digestive Disease Week (DDW-2019)
  • 11 Apr 2019 Phase-III clinical trials in Ulcerative colitis (Treatment-experienced) in Hungary (PO, Tablet) (EudraCT2018-002135-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top